Management of multiple sclerosis

New England Journal of Medicine

Volumn 337, Issue 22, 1997, Pages 1604-1611

  Rudick, Richard A ^a   Cohen, Jeffrey A ^a   Weinstock Guttman, Bianca ^a   Kinkel, Revere P ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLATIRAMER; IMMUNOGLOBULIN; METHOTREXATE; POLYPEPTIDE;

DECISION MAKING; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE SCLEROSIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 0030691881     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199711273372207     Document Type: Review

References (87)

1. Williams R, Rigby AS, Airey M, Robinson M, Ford H. Multiple sclerosis: its epidemiological, genetic, and health care impact. J Epidemiol Community Health 1995;49:563-9.
2. Proceedings of the International Conference on Therapeutic Trials in Multiple Sclerosis, Grand Island, NY, April 23-24, 1982. Arch Neurol 1983;40:663-710.
3. Ellison GW. Experimental therapies for multiple sclerosis: historical perspective. In: Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis: trial design, results, and future perspectives. London: Springer-Verlag, 1992:1-15.
4. Idem. Recent advances and future challenges in multiple sclerosis clinical trial design. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin, Germany: Springer-Verlag, 1996:1-15.
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
6. Noseworthy JH, Paty DW, Ebers, GC. Neuroimaging in multiple sclerosis. Neurol Clin 1984;2:759-77.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
9. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-8.
10. The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441-6.
11. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605.
12. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39: 1018-26.
13. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;2:179-83.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multipe sclerosis: resuts of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
15. Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis: trial design, results, and future perspectives. London: Springer-Verlag, 1992.
16. Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin, Germany: Springer-Verlag, 1996.
17. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
18. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
19. Runmaker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
20. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994; 241:597-604.
21. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:Suppl:S6-S11.
22. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-56.
23. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-41.
24. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-5.
25. Sadovnick AD, Ebers GC. Genetics of multiple sclerosis. Neurol Clin 1995;13:99-118.
26. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis: Canadian Collaborative Study Group. Nature 1995;377:150-1.
27. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nat Genet 1996;13:469-71.
28. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-6.
29. Kuokkanen S, Sundvall M, Terwilliger JD, et al. A putative vulnerability locus to multipie sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat Genet 1996;13:477-80.
30. Ben-Nun A, Lando Z. Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalomyelitis (EAE) in mice. J Immunol 1983;130. 1205-9.
31. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 1994;180:2227-37.
32. Bourdette DN, Whitham RH, Chou YK, et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994;152: 2510-9. [Erratum, J Immunol 1994;153:910.]
33. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358:155-7.
34. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp Med 1996;183:1777-88.
35. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997;99:1682-90.
36. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994;53:328-37.
37. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 1983;4:201-21.
38. Brocke S, Veromaa T, Weissman IL, Gijbels K, Steinman L. Infection and multiple sclerosis: a possible role for superantigens? Trends Microbiol 1994;2:250-4.
39. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
40. Ransohoff RM, Hamilton TA, Tani M, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993;7:592-600.
41. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-46.
42. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-8.
43. Lu HT, Riley JL, Babcock GT, et al. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med 1995;182:1517-25.
44. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-52.
45. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-63.
46. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-27.
47. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:2054-7.
48. Weinshenker BG. Clinical outcome measures for multiple sclerosis. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin, Germany: Springer-Verlag, 1996:105-22.
49. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-82.
50. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66.
51. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. I. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6.
52. Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbations: preliminary report. Arch Neurol 1968;18: Suppl:1-10.
53. Millar JH, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD. Long-term treatment of multiple sclerosis with corticotrophin. Lancet 1967;2:429-31.
54. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989;39:969-71.
55. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-9.
56. Beck RW. The Optic Neuritis Treatment Trial: three-year follow-up results. Arch Ophthalmol 1995;113:136-7.
57. Paty DW, Li DK, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
58. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis 1995;1:118-35.
59. Rudick RA, Goodkin DE, Jacobs LD, et al. The impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-63.
60. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-9.
61. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
62. Idem. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-94.
63. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-13.
64. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994;44:1537-40.
65. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies. Neurology 1996;47:865-6.
66. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14.
67. Cohen JA, Grossman RI, Udupa JK, et al. Assessment of the efficacy of copolymer-1 in the treatment of multiple sclerosis by quantitative MRI. Neurology 1995;45:Suppl:A418. abstract.
68. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
69. Lhermitte F, Marteau R, Roullet E. Not so benign long-term immunosuppression in multiple sclerosis? Lancet 1984;1:276-7.
70. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46:1607-12.
71. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-8.
72. Tippett DS, Fishman PS, Panitch HS. Relapsing transverse myelitis. Neurology 1991;41:703-6.
73. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
74. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-80.
75. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996;47:1153-7.
76. Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol 1987;44:823-7.
77. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-8.
78. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 1997;3:178-85.
79. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol 1996;36:6-16.
80. Mushlin AI, Mooney C, Grow V, Phelps CE. The value of diagnostic information to patients with suspected multiple sclerosis: Rochester-Toronto MRI Study Group. Arch Neurol 1994;51:67-72.
81. LaRocca NG, Ritvo PG, Miller DM, Fischer JS, Andrews H, Paty DW. "Quality of life" assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin, Germany: Springer-Verlag, 1996:145-60.
82. Gold DP, Smith RA, Golding AB, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ 6 CDR2 peptide. J Neuroimmunol 1997; 76:29-38.
83. Nicolle MW, Nag B, Sharma SD, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994;93:1361-9.
84. Chen Y, Inobe J, Weiner HL. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol 1995;155:910-6.
85. Noseworthy JH, O'Brien PC, van Engelen BG, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994;57: Suppl:11-4.
86. Archer DR, Cuddon PA, Lipsitz D, Duncan LD. Myelination of the canine central nervous system by glial cell transplantation: a model for repair of human myelin disease. Nat Med 1997;3:54-9.
87. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci 1996;58:1301-6.